JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Akciju saraksts・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Slēgts

1.14 4.59

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.1400000000000001

Max

1.15

Galvenie mērījumi
By Trading Economics
Ienākumi	17M -26M
Darbinieki	171
EBITDA	19M -23M

Rekomendācijas
By TipRanks
Rekomendācijas	Pārdot
Prognoze 12 mēnešiem	+266.97% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 26. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-29M 73M
Iepriekšējā atvēršanas cena	-3.45
Iepriekšējā slēgšanas cena	1.14

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.43 / 1.6 Atbalsts un pretestība

Pliant Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. febr. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 6. febr. 21:40 UTC

Iegādes, apvienošanās, pārņemšana

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026. g. 6. febr. 21:22 UTC

Tirgus saruna

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026. g. 6. febr. 21:17 UTC

Peļņas

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026. g. 6. febr. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. febr. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026. g. 6. febr. 21:13 UTC

Peļņas

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026. g. 6. febr. 21:13 UTC

Peļņas

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026. g. 6. febr. 21:04 UTC

Tirgus saruna

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026. g. 6. febr. 20:34 UTC

Peļņas

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

2026. g. 6. febr. 20:27 UTC

Peļņas

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

2026. g. 6. febr. 20:24 UTC

Tirgus saruna

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

2026. g. 6. febr. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

2026. g. 6. febr. 19:48 UTC

Peļņas

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

2026. g. 6. febr. 19:30 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

2026. g. 6. febr. 19:30 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

2026. g. 6. febr. 19:30 UTC

Iegādes, apvienošanās, pārņemšana

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

2026. g. 6. febr. 19:17 UTC

Tirgus saruna

USDA Says Farm Income to Decrease in 2026 -- Market Talk

2026. g. 6. febr. 18:50 UTC

Peļņas

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026. g. 6. febr. 18:47 UTC

Tirgus saruna

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

2026. g. 6. febr. 18:34 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

2026. g. 6. febr. 17:58 UTC

Peļņas

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

2026. g. 6. febr. 17:52 UTC

Tirgus saruna

Peļņas

Global Equities Roundup: Market Talk

2026. g. 6. febr. 17:52 UTC

Tirgus saruna

Peļņas

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

2026. g. 6. febr. 17:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 6. febr. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 6. febr. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. febr. 17:18 UTC

Tirgus saruna

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

2026. g. 6. febr. 17:09 UTC

Tirgus saruna

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pliant Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

266.97% augšup

Prognoze 12 mēnešiem

Vidējais 4 USD 266.97%

Augstākais 4 USD

Zemākais 4 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pliant Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pārdot

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pliant Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.43 / 1.6Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.